The objective of this proposal is to develop a new paradigm for Lipiodol TACE. An innovative anti-angiogenic drug-eluting microsphere platform will serve as the embolic material used during conventional TACE methods (involving Lipiodol + Doxorubicin) to enhance therapeutic outcomes. We will optimize the synthesis protocols for these sorafenib-eluting embolic microspheres and ultimately validate that the Lipiodol TACE + sorafenib-eluting embolic microsphere method permits superior outcomes in an orthotropic rodent HCC model.
|Effective start/end date||11/1/16 → 11/1/19|
- Guerbet LLC (Agmt 11/01/16)